atomoxetine hydrochloride has been researched along with Attention Deficit and Disruptive Behavior Disorders in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 15 (60.00) | 29.6817 |
2010's | 10 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Holzer, B; Lehman, R; Lopes, V | 1 |
Anagnostou, E; Baribeau, DA | 1 |
Avci, A; Bahali, K; Yalcin, O | 1 |
Alegría, AA; Brinson, H; Rubia, K | 1 |
Gardner, D; Gorman, DA; Hirsch, L; Pringsheim, T | 1 |
Hadijikoumi, I; Keen, D | 2 |
Gustafsson, PA; Hägglöf, B; Kadesjö, B; Schacht, A; Svanborg, P; Thernlund, G | 1 |
Besana, D; Bravaccio, C; Calamoneri, F; Curatolo, P; Dell'Agnello, G; Escobar, R; Mancini, F; Maschietto, D; Masi, G; Poole, L; Rossi, A; Zuddas, A | 1 |
McBurnett, K; Pfiffner, LJ | 1 |
Becker, K; D'Souza, DN; Dittmann, RW; Hazell, P; Long, A; Nikkanen, EA; Ponsler, G; Tabas, L; Tanaka, Y; Trzepacz, PT; Witcher, J | 1 |
Granger, RE; Hazell, PL; Kohn, MR; van Wyk, GW; Walton, RJ | 1 |
Dittmann, RW; Helsberg, K; Lehmann, M; Lehmkuhl, G; Schacht, A; Schneider-Fresenius, C; Wehmeier, PM | 1 |
Erder, MH; Hodgkins, PS; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J | 1 |
Banaschewski, T; Dittmann, RW; Kipp, L; Schacht, A; Wehmeier, PM | 1 |
Biederman, J; Michelson, D; Milton, DR; Newcorn, JH; Spencer, TJ | 1 |
Busner, J; Casat, C; Dittmann, R; Harder, D; Heiligenstein, J; Kaplan, S; Wernicke, JF; West, S | 1 |
Dworkin, N | 1 |
Barton, J; Benn, D; Danckaerts, M; Hazell, P; Johnson, M; Ladikos, A; Michelson, D; Wolańczyk, T; Yoran-Hegesh, R; Zeiner, P; Zhang, S; Zuddas, A | 1 |
Kelsberg, G; Rulon, EA; St Anna, L | 1 |
Biederman, J; Feldman, PD; Gao, H; Milton, DR; Newcorn, JH; Spencer, TJ; Witte, MM | 1 |
Faraone, SV; Hodgkins, P; Wigal, SB | 1 |
Ivanov, I; Newcorn, JH | 1 |
Bangerl, W; Friedrich, M; Kienbacher, C; Pellegrini, E; Scheidinger, H; Vesely, C; Wiesegger, G | 1 |
Bangs, ME; Coghill, DR; Danckaerts, M; Hazell, P; Hoare, P; Levine, L; Moore, RJ; Wehmeier, PM; Williams, DW | 1 |
10 review(s) available for atomoxetine hydrochloride and Attention Deficit and Disruptive Behavior Disorders
Article | Year |
---|---|
An update on medication management of behavioral disorders in autism.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Humans; Piperazines; Propylamines; Quinolones; Risperidone | 2014 |
Brain abnormalities in attention-deficit hyperactivity disorder: a review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain; Brain Mapping; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Conduct Disorder; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Methylphenidate; Nerve Net; Neuroimaging; Neuroprotective Agents; Positron-Emission Tomography; White Matter | 2014 |
The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysi
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Aggression; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Conduct Disorder; Humans | 2015 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Diagnostic and Statistical Manual of Mental Disorders; Humans; Methylphenidate | 2008 |
Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Central Nervous System Stimulants; Child; Child, Preschool; Humans; Practice Guidelines as Topic; Primary Health Care; Propylamines; Referral and Consultation | 2009 |
How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Hyperkinesis; Methylphenidate; Propylamines; Treatment Outcome | 2012 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Humans; Methylphenidate; Schools | 2011 |
Clinical inquiries. What are effective treatments for oppositional defiant behaviors in adolescents?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Comorbidity; Family Practice; Humans; Propylamines; Valproic Acid | 2006 |
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Personality Assessment; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Statistics as Topic | 2007 |
[Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Contraindications; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Mood Disorders; Nortriptyline; Practice Guidelines as Topic; Propylamines; Randomized Controlled Trials as Topic; Tic Disorders | 2007 |
10 trial(s) available for atomoxetine hydrochloride and Attention Deficit and Disruptive Behavior Disorders
Article | Year |
---|---|
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Propylamines; Time Factors; Treatment Outcome; Weight Gain | 2013 |
Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.
Topics: Achievement; Adaptation, Psychological; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Caregivers; Child; Child Rearing; Combined Modality Therapy; Cost of Illness; Double-Blind Method; Education; Family Conflict; Female; Harm Reduction; Humans; Male; Parenting; Propylamines; Quality of Life; Self Concept; Sweden | 2009 |
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Italy; Male; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2009 |
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Propylamines | 2009 |
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Conduct Disorder; Disease Progression; Double-Blind Method; Female; Germany; Humans; Male; Placebos; Propylamines; Treatment Outcome | 2011 |
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Norepinephrine; Propylamines | 2005 |
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Norepinephrine; Propylamines; Single-Blind Method | 2004 |
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Double-Blind Method; Female; Humans; Male; Propylamines; Recurrence; Risk; Severity of Illness Index | 2006 |
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Forecasting; Humans; Male; Problem Solving; Propylamines; Treatment Outcome; United States | 2007 |
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Multivariate Analysis; Propylamines; Treatment Outcome | 2008 |
5 other study(ies) available for atomoxetine hydrochloride and Attention Deficit and Disruptive Behavior Disorders
Article | Year |
---|---|
Atomoxetine-induced wake-time teeth clenching and sleep bruxism in a child patient.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Propylamines; Sleep Bruxism; Treatment Outcome | 2014 |
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comparative Effectiveness Research; Delayed-Action Preparations; Guanfacine; Humans; Outcome and Process Assessment, Health Care; Pharmacoepidemiology; Propylamines; Randomized Controlled Trials as Topic | 2012 |
Does Comorbid Disruptive Behavior Modify the Effects of Atomoxetine on ADHD Symptoms as Measured by a Continuous Performance Test and a Motion Tracking Device?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Comorbidity; Conduct Disorder; Double-Blind Method; Female; Humans; Male; Personality Assessment; Propylamines; Quality of Life; Reaction Time; Treatment Outcome | 2015 |
Increased blood pressure and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Norepinephrine; Propylamines | 2005 |
Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Conduct Disorder; Humans; Modafinil; Neurobiology; Pediatrics; Propylamines; Psychopharmacology; Selective Serotonin Reuptake Inhibitors; United States | 2007 |